search
Back to results

Evaluation of the Effectiveness of Standard and Innovative Products That Represent a Substitute Meal for Weight Management in a Reduction Diet in Obese Participants With Asthma

Primary Purpose

Obesity, Asthma, Overweight

Status
Recruiting
Phase
Not Applicable
Locations
Croatia
Study Type
Interventional
Intervention
Meal replacement product- STANDARD PRODUCT
Meal replacement product- INNOVATIVE PRODUCT
Sponsored by
Children's Hospital Srebrnjak
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Obesity focused on measuring obesity, asthma, overweight, nutrition

Eligibility Criteria

12 Years - 60 Years (Child, Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: adults aged 18-60, children aged 12-18 both sexes BMI >27 kg/m2 (adults); > 90th centile for BMI (children) clinical diagnosis of asthma signed informed consent Exclusion Criteria: significant comorbidities: uncontrolled diabetes mellitus requiring insulin therapy and other endocrine disorders, cardiovascular disorders and other chronic diseases (including malignancies), chronic inflammatory diseases of the gastrointestinal tract, mental disorder people who are currently on or have recently gone through a weight loss program (in the past 3 months) people who in the past 6 months had an unwanted and uncontrolled loss of body weight >5% people who underwent bariatric surgery in the past 6 months. people using drugs that increase or decrease appetite permanent therapy with steroid drugs, antidepressants, cytostatics, hormone therapy, beta-blockers, etc. people with eating disorders (bulimia) alcohol and drug addicts pregnancy, breastfeeding unstable thyroid disease

Sites / Locations

  • Children's Hospital SrebrnjakRecruiting

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

Active Comparator

No Intervention

Arm Label

Active group

Active control

Control group

Arm Description

Participants use the innovative line of products intended for body weight reduction, that represent a meal replacement for weight management.

Participants use the standard line of products intended for weight reduction that represent a meal replacement for weight management with already proven clinical effectiveness (positive control).

Participants receive personalized advice on proper nutrition for a reduction diet in which they use common food.

Outcomes

Primary Outcome Measures

BM/FM
To determine the effectiveness of a weight change diet program based on an innovative and standard product line through actual reduction of the body mass (BM) / fat mass (FM) of the participants in relation to their pre - trial body mass(BM)/fat mass (FM).

Secondary Outcome Measures

Anthropometric measurements
Change in anthropometric measurements- waist and hip circumference and waist/hip ratio and waist/height ratio Measurements of participants' waist, hip and height in meters will be taken. This multiple measurements will be aggregated and presented in ratio waist [meter] / hip [meter] and ratio waist [meter] / height [meter]
Lipid profile (triglycerides, total cholesterol, HDL, LDL)
Change of the cholesterol test/lipid panel/lipid profile (change in HDL/LDL ratio) compared to initial values
Questionnaire on quality of life
The questionnaire consists of descriptive system and visual analogue scale. The descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. The visual analogue scale records the patient's self-rated health on a vertical visual analogue scale, where the endpoints are labelled 'The best health you can imagine' and 'The worst health you can imagine'. The questionnaire is in Croatian language, with a valid and accurate translation of the corresponding original document.
Change of asthma control
ACT Questionnaire will be used to tell us if the asthma treatment plan is optimal and if asthma is being properly controlled. Maximal score is 25, where higher scores reflect greater asthma control while if the score is 19 or less that may be a sign that asthma is not controlled as well as it could be.
Change in the number of asthma exacerbations and severity
The the number of exacerbations will be recorded along with the therapy used (use of salbutamol, oral or parenteral corticosteroids etc.)

Full Information

First Posted
May 22, 2023
Last Updated
July 31, 2023
Sponsor
Children's Hospital Srebrnjak
Collaborators
Belupo, Podravka d.d.
search

1. Study Identification

Unique Protocol Identification Number
NCT05980663
Brief Title
Evaluation of the Effectiveness of Standard and Innovative Products That Represent a Substitute Meal for Weight Management in a Reduction Diet in Obese Participants With Asthma
Official Title
Randomized Stratified Controlled Clinical Study for Evaluating the Effectiveness of a Diet Program Designed for Reducing Body Weight Using Standard and Innovative Products in Obese Participants With Asthma
Study Type
Interventional

2. Study Status

Record Verification Date
July 2023
Overall Recruitment Status
Recruiting
Study Start Date
January 17, 2023 (Actual)
Primary Completion Date
September 2023 (Anticipated)
Study Completion Date
December 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Children's Hospital Srebrnjak
Collaborators
Belupo, Podravka d.d.

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Randomized stratified controlled clinical study for evaluate the effectiveness of a diet program designed for reduce body weight through standard and innovative products that are a substitute meal for weight management in a reduction diet in obese participants with asthma.
Detailed Description
In the last few decades, there has been an increase in the number of obese people to the level of a global epidemic as a result of inadequate diet, sedentary lifestyle, but also genetic predispositions. The World Health Organization (WHO) declared obesity to be the biggest, global, chronic health problem in adults, that is increasingly becoming a more serious problem than malnutrition.On the other hand, obesity is a risk factor for the development of contemporary non-infectious diseases today that account for more than 80% of mortality in developed countries, such as vascular disease, diabetes and respiratory diseases such as asthma. This trend is also recorded in Croatia, both in adult population and in children if the data from 2003 and 2015 are being compared, while according to data from 2019, almost two thirds of the adult population in Croatia were overweight or obese (42% overweight, 23% obese). Of particular concern are the data from the European Obesity Monitoring Initiative from 2018/2019. according to which in Croatia 35% of children aged 8.0 to 8.9 were overweight or obese. At the national level, the problem of obesity is greater in boys than in girls, and it is 17.8% compared to 11.9% of girls. Croatia is in a high fifth place together with other countries of the Mediterranean region of Europe due to the shift from the Mediterranean to the Western lifestyle. In cooperation with Podravka, Belupo has developed a standard and innovative product line. Products are replacing one or more one or more daily meals, and thay must comply with Regulation 2016/1413 requirements related to energy value, content and composition of fats and proteins, the amount of vitamins and minerals in this type of products. The standard product line contains common ingredients and this type of product already exists on world markets, while the innovative product line differs from the standard one by implementing raw materials that are considered better sources of potentially bioactive components. The study for a group of adult participants was designed in such a way that the participants in the initial stage follow a low-calorie diet of about 1000 - 1100 kcal, whereby 5 daily meals are replaced with meal replacements in the reduction diet (active group and active control) (intensive phase). In subsequent stages, subjects gradually increase their energy intake and gradually substitute meal replacement product (MRP) with regular nutritionally profiled meals (active phase and maintenance phase). The final (stable) phase represents the stage in which, in addition to one meal replacement per day, the usual meals designed by the nutritionists of Belupo and the Culinary Center of Podravka are consumed, where education and nutrition counseling is also carried out. The study for the child population of respondents is designed in such a way that the respondents in the initial phase implement a low-calorie diet of about 1300-1500 kcal, whereby 3 daily meals are replaced with meal replacements in the reduction diet in addition to 2 nutritionally balanced regular meals that include a minimum of 5 daily servings of fruits and vegetables (active group and active control) (intensive phase). In subsequent phases, subjects gradually increase their energy intake and gradually replace MRP with regular nutritionally profiled meals (active phase and stable phase). The final phase represents the phase in which subjects consume the usual meals designed by the nutritionists of Children's hospital Srebrnjak, where education and nutrition counseling is also carried out. The usual meals of the later stages of the study, apart from being low in energy and highly nutritionally dense are composed in such a way that they are either ready for consumption as a complete meal (e.g. ready- to eat tuna salad) or can be quickly prepared. In this way, the test respondents are directed to an adequate diet, which, by adopting proper food and lifestyle habits, will ultimately enable them to maintain the achieved reduced body weight in the long term. Study entry stage (0-2 weeks): subjects are recruited respecting the inclusion and exclusion criteria. Recruitment is carried out by a doctor. During this stage, subjects replace standard meals with meal replacement products and reduce energy intake to a final defined intake depending on the group of subjects. 200 participants in a ratio of 2:1:1 (adults and children) active group - 80 active control (positive control group) - 80 control group (negative control group) - 40 Adult participants program: The daily energy intake is defined at around 1000-1100 kcal per day, and counseling on nutrition and physical activity is carried out. Intensive phase(2-14 weeks) about 1000 - 1100 kcal/day 5 MRP (200-220 kcal per product) + 1 salad (20 kcal per portion) + water/unsweetened tea. Active phase(14-21 weeks) 1100-1200 kcal/day 3 MRP (200-220 kcal per meal) + 2 regular meals (200-280 kcal) + water/unsweetened tea. Maintenance phase (21-28 weeks): 1200-1500 kcal/day 2 MRP (200-220 kcal per meal) + 3 regular meals (260-350 kcal) + water/unsweetened tea Stable phase (28-40 weeks): 1500-2000 kcal 1 MRP (200-220 kcal per meal) + 4 regular meals (approx. 320-450 kcal) + water/unsweetened tea Usual meals can also contain snacks with lower energy values, but it is important to consume approx. 1300-1800 kcal per day with usual foods. Children participants program: The daily energy intake is defined at around 1300-1500 kcal per day, and counseling on nutrition and physical activity is carried out. Intensive phase children (weeks 2-14) around 1300-1500 kcal/day 3 MPR (200-220 kcal per product + 2 regular meals (320-400 kcal) + 1 or more salad (20 kcal per product)+ water/unsweetened tea. Active phase children (14-21 weeks) around 140-1600kcal/day 2 MPR (200-220 kcal per product) + 3 regular meals (320-400 kcal) + water/unsweetened tea. Maintenance phase (21-28 weeks): 1600-1900 kcal/day 1 MRP (200-220 kcal per meal) + 4 regular meals (350-420 kcal) + water/unsweetened tea Stable phase children (week 28-40) 1750-2250 kcal/day. 5 regular meals (350-450 kcal) + water/unsweetened tea. Snacks are included in regular meals, where the total value of meals and snacks does not exceed the total set value of regular meals.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Obesity, Asthma, Overweight
Keywords
obesity, asthma, overweight, nutrition

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Randomized stratified controlled clinical study
Masking
ParticipantCare Provider
Allocation
Randomized
Enrollment
200 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Active group
Arm Type
Experimental
Arm Description
Participants use the innovative line of products intended for body weight reduction, that represent a meal replacement for weight management.
Arm Title
Active control
Arm Type
Active Comparator
Arm Description
Participants use the standard line of products intended for weight reduction that represent a meal replacement for weight management with already proven clinical effectiveness (positive control).
Arm Title
Control group
Arm Type
No Intervention
Arm Description
Participants receive personalized advice on proper nutrition for a reduction diet in which they use common food.
Intervention Type
Dietary Supplement
Intervention Name(s)
Meal replacement product- STANDARD PRODUCT
Intervention Description
standard product line contains common ingredients and this type of product already exists on world markets
Intervention Type
Dietary Supplement
Intervention Name(s)
Meal replacement product- INNOVATIVE PRODUCT
Intervention Description
innovative product line contains raw materials that are considered better sources of potentially bioactive components
Primary Outcome Measure Information:
Title
BM/FM
Description
To determine the effectiveness of a weight change diet program based on an innovative and standard product line through actual reduction of the body mass (BM) / fat mass (FM) of the participants in relation to their pre - trial body mass(BM)/fat mass (FM).
Time Frame
every 4 weeks, through study completition (up to 9 months)
Secondary Outcome Measure Information:
Title
Anthropometric measurements
Description
Change in anthropometric measurements- waist and hip circumference and waist/hip ratio and waist/height ratio Measurements of participants' waist, hip and height in meters will be taken. This multiple measurements will be aggregated and presented in ratio waist [meter] / hip [meter] and ratio waist [meter] / height [meter]
Time Frame
every 2 months, through study completition (up to 9 months)
Title
Lipid profile (triglycerides, total cholesterol, HDL, LDL)
Description
Change of the cholesterol test/lipid panel/lipid profile (change in HDL/LDL ratio) compared to initial values
Time Frame
at 1st week of the study and after 3, 6 and 9 months, through study completition (up to 9 months)
Title
Questionnaire on quality of life
Description
The questionnaire consists of descriptive system and visual analogue scale. The descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. The visual analogue scale records the patient's self-rated health on a vertical visual analogue scale, where the endpoints are labelled 'The best health you can imagine' and 'The worst health you can imagine'. The questionnaire is in Croatian language, with a valid and accurate translation of the corresponding original document.
Time Frame
at the beginning of the study (1st week) and at the end (40th week)
Title
Change of asthma control
Description
ACT Questionnaire will be used to tell us if the asthma treatment plan is optimal and if asthma is being properly controlled. Maximal score is 25, where higher scores reflect greater asthma control while if the score is 19 or less that may be a sign that asthma is not controlled as well as it could be.
Time Frame
every 3 months, through study completition (up to 9 months)
Title
Change in the number of asthma exacerbations and severity
Description
The the number of exacerbations will be recorded along with the therapy used (use of salbutamol, oral or parenteral corticosteroids etc.)
Time Frame
every 3 months,through study completition (up to 9 months)

10. Eligibility

Sex
All
Minimum Age & Unit of Time
12 Years
Maximum Age & Unit of Time
60 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: adults aged 18-60, children aged 12-18 both sexes BMI >27 kg/m2 (adults); > 90th centile for BMI (children) clinical diagnosis of asthma signed informed consent Exclusion Criteria: significant comorbidities: uncontrolled diabetes mellitus requiring insulin therapy and other endocrine disorders, cardiovascular disorders and other chronic diseases (including malignancies), chronic inflammatory diseases of the gastrointestinal tract, mental disorder people who are currently on or have recently gone through a weight loss program (in the past 3 months) people who in the past 6 months had an unwanted and uncontrolled loss of body weight >5% people who underwent bariatric surgery in the past 6 months. people using drugs that increase or decrease appetite permanent therapy with steroid drugs, antidepressants, cytostatics, hormone therapy, beta-blockers, etc. people with eating disorders (bulimia) alcohol and drug addicts pregnancy, breastfeeding unstable thyroid disease
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Mirjana Turkalj, Prof., MD
Phone
+38516391164
Email
mturkalj@bolnica-srebrnjak.hr
Facility Information:
Facility Name
Children's Hospital Srebrnjak
City
Zagreb
ZIP/Postal Code
10000
Country
Croatia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Mirjana Turkalj, MD, PhD
Phone
+38516391164
Email
mturkalj@bolnica-srebrnjak.hr
First Name & Middle Initial & Last Name & Degree
Mirjana Turkalj, Prof,MD, PhD

12. IPD Sharing Statement

Learn more about this trial

Evaluation of the Effectiveness of Standard and Innovative Products That Represent a Substitute Meal for Weight Management in a Reduction Diet in Obese Participants With Asthma

We'll reach out to this number within 24 hrs